Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

CALGARY, March 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2008.

"In 2008, we selected our first pivotal program for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "The selection of head and neck cancers was supported by interim results reported in our US and UK clinical studies, and the successful development of a manufacturing process capable of supplying REOLYSIN for large clinical studies."

    Selected Highlights:

    Clinical Trial Results
    ----------------------

    -   Announced positive interim results from our Phase I/II UK combination
        REOLYSIN and carboplatin/paclitaxel trial. Of 14 patients evaluable
        for response, four had partial responses and five patients had stable
        disease. Of note, all partial responses and 4/5 stable diseases were
        in head and neck disease;

    -   Announced positive interim results from our UK combination REOLYSIN
        and docetaxel trial. Of the 11 patients evaluable for response, five
        had partial or minor responses, and six patients had stable disease;
        and

    -   Exceeded the primary statistical endpoint in our US multicentre,
        Phase 2 clinical trial to evaluate the intravenous administration of
        REOLYSIN in patients with various sarcomas that had metastasized to
        the lung. We reported that of 33 patients evaluable for response,
        five had stable disease for more than six months, and an additional
        10 patients had stable disease ranging from 3-6 cycles
        (cycle = 28 days).

    Clinical Trial Progress
    -----------------------

    -   Selection of first pivotal program using REOLYSIN in combination with
        paclitaxe
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized ... The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... ... in forensic DNA analysis, announced that company researchers have proven DNA evidence ... and access to DNA or a DNA database. Recognizing the need ... of forensics, Nucleix scientists have developed a novel assay termed "DNA authentication" ...
... , , ... plc (LSE: SHP, Nasdaq: SHPGY ), the global ... to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a ... across the country.* The first initiative, "RoADHD Trip," a ...
... MISSISSAUGA, ON, Aug. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: ... received a letter from the Listing Qualifications Department of ... regained compliance with Listing Rule 5550(a)(2). , We plan ... Panel ("the Panel") to review the NASDAQ,s determination of ...
Cached Biology Technology:Nucleix Researchers Discover DNA Evidence May Easily be Falsified: Company Develops New Detection Technology for Preventing Biological Identity Theft 2Nucleix Researchers Discover DNA Evidence May Easily be Falsified: Company Develops New Detection Technology for Preventing Biological Identity Theft 3Nucleix Researchers Discover DNA Evidence May Easily be Falsified: Company Develops New Detection Technology for Preventing Biological Identity Theft 4Shire Initiates Two Adult ADHD Outreach Programs 2Shire Initiates Two Adult ADHD Outreach Programs 3Shire Initiates Two Adult ADHD Outreach Programs 4Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 2
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... 9 June 2008 Elsevier, a world-leading publisher ... services, is pleased to announce the publication of ... for radical hypotheses on topics throughout the life ... to stimulate innovation by choosing work that is ...
... online journal Marine Drugs , state that an ... sea lions can result from low-dose exposure to domoic ... earlier this year led by Frances Gulland of the ... to be a newly recognized chronic disease. John ...
... influences the chances of having male or female offspring. ... Reproductive Biology and Endocrinology has demonstrated that ewes fed ... prior to conception have a significantly higher chance of ... carried out by a team of researchers from the ...
Cached Biology News:Elsevier launches Bioscience Hypotheses 2Domoic acid from toxic algal blooms may cause seizures in California sea lions 2Diet prior to pregnancy determines sheep's gender 2
... coli strain containing an overproducing clone of ... Transcriptase catalyzes the polymerization of DNA using ... copies of large mRNAs, >10 kb, may ... much lower RNase H activity than AMV ...
... Source: E. coli containing a clone of the ... Description: Topoisomerase II alters the topological state of ... through a transient break which generates a separate ... its double-stranded DNA passage mechanism, the enzyme can ...
... Topo I, Wild Type ... 1 mM DTT, 200 µM EDTA, 20% glycerol, ... I (Topo I) is a monomeric protein of ... It catalyzes the relaxation of both positive and ...
Request Info...
Biology Products: